Stocks Health care SGMOQ
OTC · Health careSangamo Therapeutics, Inc (SGMOQ)
Sangamo Therapeutics, Inc brought in $34.6M of revenue over the twelve months to March 31, 2026, down 45.8% from a year earlier. It posted a net loss of $123.3M. In fiscal 2025 capital spending exceeded operating cash flow by $97.3M. At March 31, 2026 it held $27.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on May 14, 2026.
Watch SGMOQ in 60 secondsWhat Sangamo Therapeutics, Inc does
Sangamo Therapeutics, Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker SGMOQ.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $39.6M | -$122.9M | -$0.44 | -$97.3M |
| 2024 | $57.8M | -$97.9M | -$0.49 | -$67.4M |
| 2023 | $176.2M | -$257.8M | -$1.48 | -$246M |
| 2022 | $111.3M | -$192.3M | -$1.25 | -$243.8M |
| 2021 | $110.7M | -$178.3M | -$1.23 | -$256.5M |
| 2020 | $118.2M | -$121M | -$0.90 | $155.2M |
Full financial statements: income, balance sheet and cash flow
Where SGMOQ ranks in Health care
Latest SEC filings
What Sangamo Therapeutics, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026
- September 8, 2026
- August 28, 2026
- August 17, 2026Late quarterly report notice NT 10-Q
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Other event 8-K
- August 12, 2026
- July 20, 2026
- July 1, 2026Auditor change 8-K
- June 23, 2026Exhibits 8-K/A
Insider trades
What the people running Sangamo Therapeutics, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 25, 2026 | Macrae SandyPRESIDENT, CEO AND DIRECTOR, Director | Shares withheld for tax | 12,613 | $2.2K |
| May 25, 2026 | Willoughby Scott B.SVP, CHIEF LEGAL OFFICER, SECY | Shares withheld for tax | 4,036 | $703.5 |
| May 25, 2026 | Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER | Shares withheld for tax | 4,036 | $703.5 |
| May 25, 2026 | Davis Gregory DHead of Research & Technology | Shares withheld for tax | 1,630 | $284.1 |
| May 25, 2026 | Jain NikunjPrincipal Accounting Officer | Shares withheld for tax | 1,919 | $334.5 |
| April 22, 2026 | Davis Gregory DHead of Research & Technology | Sold | 69,827 | $17.7K |
| April 21, 2026 | Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER | Sold | 345,942 | $89.2K |
Who owns SGMOQ
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 9.38% | August 14, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 3,220,092 shares in total, about $454K at the last price.
| Holder | Shares |
|---|---|
| Macrae SandyPRESIDENT, CEO AND DIRECTOR, Director | 1,895,043 |
| Willoughby Scott B.SVP, CHIEF LEGAL OFFICER, SECY | 647,370 |
| Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER | 328,733 |
| Jain NikunjPrincipal Accounting Officer | 235,292 |
| Davis Gregory DHead of Research & Technology | 113,654 |
Questions about SGMOQ
What does Sangamo Therapeutics, Inc do?
Sangamo Therapeutics, Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker SGMOQ.
Is Sangamo Therapeutics, Inc profitable?
No. Over the twelve months to March 31, 2026 it reported a net loss of $123.3M on revenue of $34.6M.
How much revenue does Sangamo Therapeutics, Inc make?
Over the twelve months to March 31, 2026 Sangamo Therapeutics, Inc reported revenue of $34.6M. That is 45.8% less than a year earlier.
When did Sangamo Therapeutics, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on May 14, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the bankruptcy or receivership from September 21, 2026.
Similar companies
Compare SGMOQ with
Compare SGMOQ with any company
Follow SGMOQ
Get an email when Sangamo Therapeutics, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow SGMOQ: get an email when it filesWhere the numbers come from
Financial figures are the values Sangamo Therapeutics, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.